Anti-amyloid Monoclonal Antibody (mAb)
Phase 2Small molecule
Anti-amyloid Monoclonal Antibody (mAb) is one of 3 small molecule programs targeting Preclinical Alzheimer's Disease. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Preclinical Alzheimer's Disease
#DrugCompanyPhaseTrials
1Kisunla
Eli LillyPhase 3
Obicetrapib
NNewAmsterdam Pharma
Phase 2
Anti-amyloid Monoclonal Antibody (mAb)
PPaul S. Aisen
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- PPaul S. Aisen